CPT-Pharmacometrics & Systems Pharmacology

Papers
(The H4-Index of CPT-Pharmacometrics & Systems Pharmacology is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Issue Information44
Issue Information42
Issue Information41
Correction to Network module‐based drug repositioning for pulmonary arterial hypertension34
Issue Information28
Pharmacometric and statistical considerations for dose optimization28
Prediction of a CLDN18.2 Targeted Antibody Drug Conjugate Pharmacokinetics in Cancer Patients Using PBPK Modeling and Simulation28
Pharmacokinetics of Intrapartum Benzylpenicillin: Insights Into Candidate Regimens to Prevent Early Onset Neonatal Group B Streptococcus Disease27
A case‐study of model‐informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II26
Physiologically‐based pharmacokinetic model of sparsentan to evaluate drug–drug interaction potential26
Clinical pharmacokinetics of leriglitazone and a translational approach using PBPK modeling to guide the selection of the starting dose in children26
Issue Information26
Development of a physiologically based pharmacokinetic model of fostemsavir and its pivotal application to support dosing in pregnancy25
Exposure–response modeling for nausea incidence for cotadutide using a Markov modeling approach25
Increasing application of pediatric physiologically based pharmacokinetic models across academic and industry organizations24
A systematic efficacy analysis of tuberculosis treatment with BPaL‐containing regimens using a multiscale modeling approach24
Evaluation of covariate effects in item response theory models24
Evaluation of postprandial total triglycerides within the TIGG model for characterizing postprandial response of glucose, insulin, and GLP‐124
Physiologically‐based pharmacokinetic modeling of pantoprazole to evaluate the role of CYP2C19 genetic variation and obesity in the pediatric population23
Translational Physiologically Based Pharmacokinetic Modeling to Predict Human Pulmonary Kinetics After Lung Delivery22
A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP‐1 dual agonist22
Quantitative Systems Pharmacology Model to Predict Target Occupancy by Bruton Tyrosine Kinase Inhibitors in Patients With B‐Cell Malignancies21
Designing phase I oncology dose escalation using dose–exposure–toxicity models as a complementary approach to model‐based dose–toxicity models21
Association between SARS‐CoV‐2 viral kinetics and clinical score evolution in hospitalized patients21
0.2298378944397